ANIK
ANIK
NASDAQ · Biotechnology

Anika Therapeutics Inc

$20.34
-0.34 (-1.64%)
As of Sep 29, 2:50 PM ET ·
Financial Highlights (FY 2026)
Revenue
105.35M
Net Income
-10,159,897
Gross Margin
56.6%
Profit Margin
-9.6%
Rev Growth
-10.3%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 105.35M 117.42M 23.45M 26.68M
Gross Profit 59.58M 66.41M 6.64M 7.56M
Operating Income -10,324,105 -10,356,324 6.55M 7.58M
Net Income -10,159,897 -10,191,604 5.38M 7.18M
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Rev Growth -10.3% -10.3% -4.1% +21.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.69M 41.86M
Total Equity — — 99.18M 96.99M
D/E Ratio — — 0.39 0.43
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -5,303,552 -5,615,664 8.65M 11.22M
Free Cash Flow — — 4.59M 6.09M